Noble Capital Gives Oncology Institute (TOI) Outperform Rating

The Oncology Institute, Inc. (NASDAQ:TOI) is one of the 10 Best Performing Penny Stocks So Far in 2025. On July 23, Noble Capital initiated coverage of The Oncology Institute, Inc. (NASDAQ:TOI), giving the stock an “Outperform” rating and setting the price target at $8.

The private equity research firm highlighted that The Oncology Institute, Inc.’s (NASDAQ:TOI) treatment regimens have helped improve patient outcomes while also cutting down care costs.

Noble Capital Gives Oncology Institute (TOI) Outperform Rating

A radiologist monitoring the progress of radiation therapy on a patient.

According to Noble Capital, the company is well-positioned to benefit from current healthcare trends like the need to control medical costs and small medical practice consolidation. The firm values The Oncology Institute, Inc. (NASDAQ:TOI) at 1.25 times its estimated revenues for the fiscal year of 2026. Noble Capital projects the company will reach $583.4 million in revenues by 2026.

The Oncology Institute, Inc. (NASDAQ:TOI) is an American company that specializes in community-based cancer care services.

While we acknowledge the potential of TOI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TOI and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Best American Semiconductor Stocks to Buy Now and 11 Best Fintech Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.